CosmosID Competitors and Similar CompaniesClear all
CosmosID's competitors and similar companies include Metabolon, Adaptimmune, PolyPid and VBI Vaccines.
 CosmosID CosmosID develops softwarefor identifyingpathogens present in clinical, environmental, and other research samples. |  Metabolon Global leader in metabolomics for precision medicine, biomarker discovery, and advancing pharma & life sciences research. |  Adaptimmune Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. |  PolyPid PolyPid is a company developing a technology platform that enables a controlled and prolonged release of active pharmaceutical ingredients (API). |  VBI Vaccines VBI Vaccines is a biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. | |
Founding Date | Founding Date 2008 | Founding Date 2000 | Founding Date 2008 | Founding Date 2008 | Founding Date 2001 |
Type | Type Private | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Germantown, US HQ Södertälje, SE | Locations Morrisville, US HQ Hallbergmoos, DE München, DE | Locations Philadelphia, US HQ Milton, GB Milton, GB Stevenage, GB | Locations Petah Tikva, IL HQ Summit, US | Locations Cambridge, US HQ Ottawa, CA Rehovot, IL |
Employees | Employees 25 | Employees 1911% increase | Employees 4007% decrease | Employees 57 | Employees 12314% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 188.5 m | Valuation ($) 23.7 m | Valuation ($) 1.9 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $178m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $8.7m (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $70k (FY, 2024) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $178m (FY, 2024) | Gross profit N/A | Gross profit N/A |
Net income | Net income N/A | Net income N/A | Net income ($70.8m) (FY, 2024) | Net income ($34.2m) (FY, 2025) | Net income ($92.8m) (FY, 2023) |
Operating ⚠ | |||||
Patent Applications | Patent Applications N/A | Patent Applications N/A | Patent Applications 69 (FY, 2016) | Patent Applications 49 (FY, 2017) | Patent Applications N/A |
Patents Issued | Patents Issued N/A | Patents Issued N/A | Patents Issued 173 (FY, 2016) | Patents Issued 104 (FY, 2017) | Patents Issued N/A |
Funding | |||||
Latest funding round | Latest funding round $ 6m (over 10 years ago) | Latest funding round $ 15m (over 9 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 7.2m | Total funding raised $ 95.4m | Total funding raised $ 107.5m | Total funding raised $ 103.8m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Metabolon
HQ
Morrisville, US
Employees
191↑ 1% increase
Global leader in metabolomics for precision medicine, biomarker discovery, and advancing pharma & life sciences research.
View companyAdaptimmune
HQ
Philadelphia, US
Employees
400↓ 7% decrease
Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
View companyPolyPid
HQ
Petah Tikva, IL
Employees
57
PolyPid is a company developing a technology platform that enables a controlled and prolonged release of active pharmaceutical ingredients (API).
View companyVBI Vaccines
HQ
Cambridge, US
Employees
123↑ 14% increase
VBI Vaccines is a biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.
View company